Related Experiment Video

Updated: Apr 18, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

668

Teneligliptin : expectations for its pleiotropic action

Ryuichi Morishita1, Hironori Nakagami

  • 1Osaka University, School of Medicine, Department of Clinical Gene Therapy , 2-2 Yamada-oka, Suita 565-0871, Osaka , Japan +81 6 6879 3406 ; +81 6 6879 3409 ; morishit@cgt.med.osaka-u.ac.jp.

Expert Opinion on Pharmacotherapy
|January 20, 2015
PubMed
Abstract

Insights

Improved glucose control in diabetes mellitus is crucial for preventing complications. Teneligliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, shows potential in managing glycemic fluctuations and vascular health.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Vascular Biology

Background:

  • Diabetes mellitus management aims to prevent complications.
  • Glucose fluctuations increase the risk of diabetic vascular complications.
  • Effective pharmacotherapy requires control of hyperglycemia and glucose variability.

Purpose of the Study:

  • To review the pleiotropic effects of teneligliptin.
  • To examine the potential clinical relevance of teneligliptin's effects on endothelial function and metabolic syndrome.

Main Methods:

  • Review of pre-clinical and clinical studies on DPP-4 inhibitors, specifically teneligliptin.
  • Analysis of teneligliptin's structural and pharmacokinetic characteristics.
  • Evaluation of teneligliptin's impact on glycemic control and vascular function.

Main Results:

  • Teneligliptin demonstrates potent and sustained glycemic control.
  • It reduces risks associated with hypoglycemia and postprandial hyperglycemia.
  • Potential vasoprotective effects and benefits for cardiovascular disease risk are suggested.

Conclusions:

  • Teneligliptin's pleiotropic effects, including on endothelial function and metabolic syndrome, warrant further investigation.
  • These effects may offer significant clinical benefits for diabetic patients.
  • Teneligliptin represents a promising therapeutic option in diabetes pharmacotherapy.
Keywords:
diabetes mellitusdipeptidyl peptidase-4 inhibitorsglucose fluctuationsglycemic controlteneligliptinvascular function

More Related Videos

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

5.9K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000